Fierce Pharma
DECEMBER 6, 2023
With an FDA approval in PNH, Novartis has gained its first nod for iptacopan, dubbed two months ago “a pipeline in pill," by analysts at ODDO BHF.
Clarivate
DECEMBER 6, 2023
Students and researchers can easily locate new sources of research on diverse topics with the enriched ProQuest Dissertations & Theses Citation Index, as well as easily showcase their work and monitor impact over time. An academic career can be rewarding, but also marked by high stress [1]. Today’s researchers are challenged to balance multiple priorities and deadlines – from securing adequate funding for their work, to meeting the demands of a full teaching workload — all while publishing r
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
DECEMBER 6, 2023
After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. | In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. Many years later, Novartis is settling the case.
MedCity News
DECEMBER 6, 2023
CB Insights released a list of what it deems to be the 50 most promising digital health companies of 2023. The market research firm said that the startups on the list are working to improve four main aspects of healthcare: personalization, efficiency, equity and accessibility.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
DECEMBER 6, 2023
Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial. | Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial.
PharmExec
DECEMBER 6, 2023
Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 6, 2023
Seattle Children's launched BrainChild Bio to focus on expediting the development of CAR T-cell therapies in central nervous system tumours.
European Pharmaceutical Review
DECEMBER 6, 2023
In an early human study , US researchers have found that combining immunotherapy with dupilumab, an Interleukin-4 (IL-4) receptor-blocking antibody, boosted the immune system of lung cancer patients. Dupilumab is used widely as an allergy and asthma treatment, stated the authors of the corresponding research paper, which has been published in Nature.
MedCity News
DECEMBER 6, 2023
Canopy has emerged from stealth as a startup focused on protecting healthcare staff from increasing levels of violence. The company’s product, called Canopy Protect, involves wearable monitors that healthcare staff can press when they feel threatened, as well as a system that allows a hospital to monitor all physical areas of the organization.
European Pharmaceutical Review
DECEMBER 6, 2023
The US Food and Drug Administration (FDA) has approved the first oral monotherapy treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH). Novartis’ Factor B inhibitor, Fabhalta ® (iptacopan) provides comprehensive control of red blood cell (RBC) destruction, according to the company. Novartis releases data for potentially “practice-changing” PNH medicine Key Phase III data for iptacopan “In clinical studies, iptacopan was superior to anti-C5s in haemoglobin improv
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
DECEMBER 6, 2023
Through rigorous validation processes, unwavering transparency, gradual implementation, and a steadfast commitment to preserving the human touch, healthcare IT providers can unequivocally demonstrate that AI is a reliable and trustworthy ally in the intricate and evolving landscape of healthcare.
European Pharmaceutical Review
DECEMBER 6, 2023
In the interview, conducted at CPHI Barcelona, Krishna Venkatesh, Global Head, Sterile Manufacturing Operations at Dr Reddy’s Laboratories explores industry’s growing focus on achieving end-to-end connectivity, as well as the potential of automation and track and trace solutions. Venkatesh, who is responsible for sterile injectable manufacturing and operations within Dr Reddy’s global organisation, also emphasises the role of data analytics, artificial intelligence, and low-cost automation
MedCity News
DECEMBER 6, 2023
FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.
pharmaphorum
DECEMBER 6, 2023
Sanofi has deepened an existing collaboration with artificial intelligence specialist Aqemia in the latest among a flurry of collaborations between pharma companies and generative AI (genAI) companies. The French pharma group has signed a multi-year agreement with Paris-based Aqemia, focused on the discovery of small-molecule drug candidates across multiple therapeutic categories, through the application of genAI and deep physics algorithms that can model molecular interactions.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
DECEMBER 6, 2023
Dr. Wendaline VanBuren, a radiology chair at Mayo Clinic, thinks that AI is in the beginning stages of improving radiologists’ workflows. Some of the most developed radiology AI research projects at Mayo center on image segmentation and 3D printing, she said. In the future, she’s excited to see more tools that aid radiologists in triage and lesion measurement.
PharmExec
DECEMBER 6, 2023
National Library of Medicine study emphasizes inadequacies in ensuring the safety and efficacy of over-the-counter dietary supplements.
MedCity News
DECEMBER 6, 2023
Too often, executives look to data retrospectively to understand what has happened, rather than using data prescriptively to understand what is likely to happen and, in turn, how to best respond.
Pharmaceutical Technology
DECEMBER 6, 2023
IGM will lay off 22% of its staff and suspend four clinical activities to advance autoimmune diseases and colorectal cancer programmes.
MedCity News
DECEMBER 6, 2023
Recognizing and responding to this new emphasis on patient engagement isn’t easy. It requires providers to abandon a long-held model of healthcare with clinicians squarely at the center in favor of one in which the patients are in charge – and easily lost – if their wishes are not met.
PharmaTimes
DECEMBER 6, 2023
The neurological condition currently affects one in 300 people in the UK - News - PharmaTimes
MedCity News
DECEMBER 6, 2023
Our current system is broken. It only allows for the evaluation of symptoms and the treatment of disease. We need to adapt to the reality of an aging population and encourage everyone to age well.
PharmaVoice
DECEMBER 6, 2023
This year’s many firsts included a vaccine for RSV and a drug that slows Alzheimer’s disease.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
MedCity News
DECEMBER 6, 2023
UI affects 78 million women in the U.S. while fecal incontinence affects 12 million. Prevalence is rising. Age and obesity are associated with increased risk of UI, and both contribute to its increased incidence. Globally, hundreds of millions of women are affected.
PharmExec
DECEMBER 6, 2023
An overview of the nine biggest developments to expect across the healthcare industry in the year ahead.
MedCity News
DECEMBER 6, 2023
Many new to financing negotiations try to paint a rosy picture and offer unrealistic terms or revenue expectations to improve a soured relationship. This will quickly backfire and result in defaults, which not only incurs additional costs, but can rupture trust and spoil relationships.
PharmaTimes
DECEMBER 6, 2023
The commitments will make health systems faster, simpler and fairer for patients - News - PharmaTimes
pharmaphorum
DECEMBER 6, 2023
Daiichi Sankyo unit claims $182m in Novartis patent dispute Phil.
Pharmaceutical Commerce
DECEMBER 6, 2023
Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.
Clarivate
DECEMBER 6, 2023
By the year 2030, it is likely the legal space will look and operate differently to today, resulting in reshaping the way IP professionals at law firms and in-house councils work. What could this mean for the future of the IP legal profession? Today’s global workforce is experiencing significant, swift and continuous shifts. Customer needs are evolving.
pharmaphorum
DECEMBER 6, 2023
Merck pummelled as MS hope fenebrutinib dies in phase 3 Phil.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
334 
Let's personalize your content